| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 07/16/2009 | CA2710679A1 Inhibitors of cytochrome p450 |
| 07/16/2009 | CA2710651A1 Mixture of citric flavonoids to improve ruminal fermentation |
| 07/16/2009 | CA2710525A1 Nanodispersion |
| 07/16/2009 | CA2709992A1 Pharmaceutical composition |
| 07/16/2009 | CA2709660A1 Compositions comprising unsaturated fatty acids and nitric oxide releasing compounds and use thereof for enhancing congnitive and related functions |
| 07/16/2009 | CA2709521A1 Novel coated extended release pharmaceutical compositions of levetiracetam |
| 07/16/2009 | CA2708961A1 (het)aryl-p-quinone derivatives for treatment of mitochondrial diseases |
| 07/16/2009 | CA2708921A1 Use of cannabinoids in combination with an anti-psychotic medicament |
| 07/16/2009 | CA2707441A1 Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same |
| 07/16/2009 | CA2706931A1 Oral pharmaceutical dosage forms |
| 07/16/2009 | CA2706028A1 Composition comprising a nitrooxyderivative of acetaminophen and a anticonvulsant drug for the treatment of neuropathic pain |
| 07/16/2009 | CA2703824A1 Modulators for amyloid beta |
| 07/16/2009 | CA2702992A1 Methods of inhibiting bacterial virulence and compounds relating thereto |
| 07/16/2009 | CA2702791A1 6-aryl/heteroalkyloxy benzothiazole and benzimidazole derivatives, method for preparing same, application thereof as drugs, pharmaceutical compositions and novel use in particularas c-met inhibitors |
| 07/16/2009 | CA2702012A1 5,6-diaryl pyridines substituted in the 2- and 3-position, preparation thereof and therapeutic use thereof |
| 07/16/2009 | CA2692955A1 A new method for preparation of zopiclone and its polymorphs |
| 07/16/2009 | CA2676477A1 Crystalline solvated forms of (r)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1h-benzimidazole |
| 07/15/2009 | EP2078720A1 Novel method for the preparation of derivatives of dihydrotetraazapentacenes, products such as obtained and uses thereof |
| 07/15/2009 | EP2078719A1 Compound having bicyclic pyrimidine structure and pharmaceutical composition comprising the compound |
| 07/15/2009 | EP2078718A1 N-aryl diazaspiracyclic compounds and methods of preparation and use thereof |
| 07/15/2009 | EP2078717A1 6-Pyrimidinyl-pyrimid-2-one derivative |
| 07/15/2009 | EP2078716A1 New derivatives of 1H-indol-1-yl-urea, method for preparing same and pharmaceutical compositions containing them |
| 07/15/2009 | EP2078713A1 Inhibitors of biofilm formation of gram-positive and gram-negative bacteria |
| 07/15/2009 | EP2078712A1 Indole derivatives as selective androgen receptor modulators (sarms) |
| 07/15/2009 | EP2078711A1 (Aza)indole derivative substituted in position 5, pharmaceutical composition comprising it, intermediate compounds and preparation process therefor |
| 07/15/2009 | EP2078528A1 Radiation sensitizer or anti-cancer chemotherapy sensitizer |
| 07/15/2009 | EP2078527A1 Aqueous liquid preparation comprising gatifloxacin |
| 07/15/2009 | EP2078526A1 Aqueous liquid preparation having improved intraocular gatifloxacin penetration |
| 07/15/2009 | EP2078525A2 Treatment of tuberculosis using immunomodulator compounds |
| 07/15/2009 | EP2078524A1 Adhesive skin patch |
| 07/15/2009 | EP2078523A1 Agent for suppression of gastric emptying comprising 4-hydroxyisoleucine |
| 07/15/2009 | EP2078522A1 Composition for treating allergy |
| 07/15/2009 | EP2078080A2 Cpg oligonucleotide analogs containing hydrophobic t analogs with enhanced immunostimulatory activity |
| 07/15/2009 | EP2078032A2 Compositions and methods for suppressing endometrial proliferation |
| 07/15/2009 | EP2078031A2 Monoesters of estrogens with conjugated linoleic acid and uses thereof |
| 07/15/2009 | EP2078029A2 Enantiomerically pure phosphoindoles as hiv inhibitors |
| 07/15/2009 | EP2078027A1 Cathepsin proteases inhibitors |
| 07/15/2009 | EP2078026A1 Prodrug salts of 2, 4-pyrimidinediamine compounds and their uses |
| 07/15/2009 | EP2078025A2 Process for the synthesis of clopidogrel and new forms of pharmaceutically acceptable salts thereof |
| 07/15/2009 | EP2078024A1 Amorphous asenapine and processes for preparing same |
| 07/15/2009 | EP2078023A1 Tetrahydrofuro (3, 2-b) pyrrol-3-one derivatives as inhibitors of cysteine proteinases |
| 07/15/2009 | EP2078022A1 Spiro benzazepines used as vasopressin antagonists |
| 07/15/2009 | EP2078021A2 Pyrazolopyrimidine analogs and their use as mtor kinase and pi3 kinase inhibitors |
| 07/15/2009 | EP2078020A1 Fused ring heterocycle kinase modulators |
| 07/15/2009 | EP2078019A2 Purines as pkc-theta inhibitors |
| 07/15/2009 | EP2078018A1 Heteroaryl compounds, compositions thereof, and use thereof as protein kinase inhibitors |
| 07/15/2009 | EP2078015A2 Modulators of glucocorticoid receptor, ap-1 and/or nf-kappab activity and use thereof |
| 07/15/2009 | EP2078014A2 Crystalline and amorphous forms of tiagabine |
| 07/15/2009 | EP2078012A2 Thrombin receptor antagonists based on the modified tricyclic unit of himbacine |
| 07/15/2009 | EP2078010A2 Polycyclic heteroaryl substituted triazoles useful as axl inhibitors |
| 07/15/2009 | EP2078009A1 New fluorene derivatives, compositions containing the same and use thereof as inhibitors of the protein chaperone hsp 90 |
| 07/15/2009 | EP2078007A1 Ikk-beta serine-threonine protein kinase inhibitors |
| 07/15/2009 | EP2078004A1 2-aminothiazole-4-carboxylic amides as protein kinase inhibitors |
| 07/15/2009 | EP2078003A1 Anilinopiperazine derivatives and methods of use thereof |
| 07/15/2009 | EP2078002A1 2-aminothiazole-4-carboxylic amides as protein kinase inhibitors |
| 07/15/2009 | EP2078001A1 Diazepane-acetamide derivatives as selective 11 -hsd1 inhibitors |
| 07/15/2009 | EP2078000A1 Benzoyl amino heterocyclyl compounds as glucokinase (glk) activators |
| 07/15/2009 | EP2077999A1 Hydroxamates as inhibitors of histone deacetylase |
| 07/15/2009 | EP2077998A1 Phthalazine, aza- and diaza-phthalazine compounds and methods of use |
| 07/15/2009 | EP2077996A1 Purification process of montelukast and its amine salts |
| 07/15/2009 | EP2077995A1 Methods of synthesizing pharmaceutical salts of a factor xa inhibitor |
| 07/15/2009 | EP2077994A1 Crystalline s-(-)-amlodipine adipic acid salt anhydrous and preparation method thereof |
| 07/15/2009 | EP2077993A1 Method for the separation of s-(-)-amlodipine from racemic amlodipine |
| 07/15/2009 | EP2077992A2 Indole antagonists of p2y1 receptor useful in the treatment of thrombotic conditions |
| 07/15/2009 | EP2077903A2 Process for the preparation of form i and form ii of ritonavir |
| 07/15/2009 | EP2077851A1 A pharmaceutical composition comprising cordycepin for the treatment and prevention of obesity |
| 07/15/2009 | EP2077850A2 Elvucitabine pharmaceutical compositions |
| 07/15/2009 | EP2077849A1 Use of compounds of the avermectin family for the treatment of dermatological disorders in human beings |
| 07/15/2009 | EP2077848A1 Use of compounds of the avermectin family for the treatment of dermatological disorders |
| 07/15/2009 | EP2077847A2 Halogenated alkyl di- and trisaccharides, pharmaceutical formulations, diagnostic kits and methods of treatment |
| 07/15/2009 | EP2077846A2 Benzoxazepine compounds, their preparation and use |
| 07/15/2009 | EP2077845A2 Macrocyclic quinazoline derivatives as vegfr3 inhibitors |
| 07/15/2009 | EP2077844A2 Method of treqatment and compositions of d-chriro inositol and phosphates thereof |
| 07/15/2009 | EP2077843A1 Use of a mt kinase inhibitor for treating or preventing brain cancer |
| 07/15/2009 | EP2077842A2 Use of an egfr antagonist for the treatment of glomerolonephritis |
| 07/15/2009 | EP2077841A1 Novel substituted pyrimidines as cysteine protease inhibitors |
| 07/15/2009 | EP2077840A1 Aqueous pharmaceutical suspensions containing rebamipide and manufacturing process thereof |
| 07/15/2009 | EP2077839A2 Soluble epoxide hydrolase inhibitors for the treatment of rheumatoid arthritis |
| 07/15/2009 | EP2077838A2 Methods for the treatment of a related disorders and compositions therefor |
| 07/15/2009 | EP2077837A2 Derivatives of pyrrolizine, indolizine and quinolizine, preparation thereof and therapeutic use thereof |
| 07/15/2009 | EP2077836A2 Antidepressant, neuroprotectant, amyloid beta deposition inhibitor or age retardant containing heterocyclic compound |
| 07/15/2009 | EP2077835A2 An alzheimer's disease progression inhibitor containing heterocyclic compound |
| 07/15/2009 | EP2077834A2 Formulations of phospholipase enzyme inhibitors |
| 07/15/2009 | EP2077833A1 Use of compounds of the milbemycin family for the treatment of dermatological disorders in human beings |
| 07/15/2009 | EP2077832A1 Use of compounds of the avermectin family for the treatment of dermatological disorders in human beings |
| 07/15/2009 | EP2077831A2 Use of 6'-ethyl-lepimectine, 6'-methyl-lepimectine or derivatives thereof for the treatment of dermatological disorders in human beings |
| 07/15/2009 | EP2077830A1 Methods, compositions, and formulations for the treatment of thyroid eye disease |
| 07/15/2009 | EP2077829A2 Pai-1 binding modulators for the treatment of ocular disorders |
| 07/15/2009 | EP2077828A2 Treatment of hepatic encephalopathy and liver cirrhosis |
| 07/15/2009 | EP2077827A1 Oleanane triterpene saponin compounds which are effective on treatment of dementia and mild cognitive impairment(mci), and improvement of cognitive function |
| 07/15/2009 | EP2077826A2 Method to enhance tissue regeneration |
| 07/15/2009 | EP2077825A2 Liquid formulations of phospholipase enzyme inhibitors |
| 07/15/2009 | EP2077822A1 Oxcarbazepine-containing oral formulation and a process to obtain the same |
| 07/15/2009 | EP2077819A2 Methods, kits, and compositions for generating new hair follicles and growing hair |
| 07/15/2009 | EP2077719A2 Piperidine and pyrrolidine beta-secretase inhibitors for the treatment of alzheimer's disease |
| 07/15/2009 | EP2005962A9 Therapeutic agent for inflammatory bowel disease |
| 07/15/2009 | EP2005954A9 Kit for cancer therapy and pharmaceutical composition for cancer therapy |
| 07/15/2009 | EP1996603B1 Lipid a antagonists with anti-septic shock, anti-inflammatory, anti-ischemia and analgesic activity |
| 07/15/2009 | EP1996199A4 Rapidly dissolving solid oral dosage form for delivery of composition for increasing nitric oxide activity |
| 07/15/2009 | EP1994062B1 Aryl/alkyl vinyl sulfone hyaluronic acid derivatives |